A multicenter, open, noncomparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, granulocyte colony-stimulating factor and mitoxantrone as induction therapy in refractory acute myeloid leukemia: A report of the Polish Adult Leukemia Group

Annals of Hematology

Volumn 84, Issue 9, 2005, Pages 557-564

  Wrzesien Kus A ^a   Robak, Tad ^a   Wierzbowska, A ^a   Lech Maranda E ^a   Pluta, A ^a   Wawrzyniak, E ^a   Krawczynska A ^a   Kuliczkowski, K ^b   Mazur, G ^b   Kiebinski M ^b   Dmoszynska A ^c   Wach, M ^c   Hellmann, A ^c   Baran, W ^d   Holowiecki J ^e   Kyrcz Krzemien S ^e   Grosicki, S ^e  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

^c MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^d MEDICAL UNIVERSITY OF GDANSK   (Poland)

^e MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

2 Chlorodeoxyadenosine; Cladribine; Induction treatment; Mitoxantrone; Purine nucleoside analogs; Refractory AML

Indexed keywords

CLADRIBINE; CYTARABINE; MITOXANTRONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALOPECIA; ANTINEOPLASTIC ACTIVITY; APLASIA; ARTICLE; BLEEDING; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER REGISTRY; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INFUSION; DRUG MEGADOSE; DRUG SAFETY; FEMALE; FEVER; HUMAN; LIVER TOXICITY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MYCOSIS; OPEN STUDY; PHASE 2 CLINICAL TRIAL; POLAND; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; SEPSIS; STATISTICAL SIGNIFICANCE; STOMATITIS;

ACUTE DISEASE; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLADRIBINE; CYTARABINE; DRUG THERAPY, COMBINATION; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOLOGIC DISEASES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; MITOXANTRONE; REMISSION INDUCTION; SALVAGE THERAPY; SURVIVAL ANALYSIS;

EID: 23944456658     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-005-1046-0     Document Type: Article

References (39)

1. Archimbaud E, Thomas X, Leblond V, Michallet M, Fenaux P, Cordonnier C, Dreyfus F, Troussard X, Jaubert J, Travade P et al (1995) Timed sequential chemotherapy for previously treated patients with acute myeloid leukemia: Long-term follow-up of the etoposide, mitoxantrone, and cytarabine-86 trial. J Clin Oncol 13:11-18 1:STN:280:ByqD1MnptlE%3D
2. Carella AM, Cascavilla N, Greco MM, Melillo M, Sajeva MR, Ladogana S, D'Arena G, Perla G, Carotenuto M (2001) Treatment of "poor risk" acute myeloid leukemia with fludarabine, cytarabine and G-CSF (flag regimen): A single center study. Leuk Lymphoma 40:295-0303 1:CAS:528:DC%2BD3MXjs1Wjt7o%3D
3. Cheson BD, Cassileth PA, Head DR, Schiffer CA, Bennett JM, Bloomfield CD, Brunning R, Gale RP, Grever MR, Keating MJ (1990) Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 8:813-819 1:STN:280:By%2BB3sjotlE%3D
4. Clavio M, Carrara P, Miglino M, Pierri I, Canepa L, Balleari E, Gatti AM, Cerri R, Celesti L, Vallebella E, Sessarego M, Patrone F, Ghio R, Damasio E, Gobbi M (1996) High efficacy of fludarabine containing therapy (FLAG-FLANG) in poor risk acute myeloid leukemia. Haematologica 81:513-520 1:CAS:528:DyaK2sXhvVehtrk%3D
5. Clavio M, Venturino C, Pierri I, Garrone A, Miglino M, Canepa L, Balleari E, Balocco M, Michelis GL, Ballerini F, Gobbi M (2004) Combination of liposomal daunorubicin (DaunoXome), fludarabine, and cytarabine (FLAD) in patients with poor-risk acute leukemia. Ann Hematol 83:696-703 10.1007/s00277-004-0927-y
6. Cortes J, Estey E, Beran M, O'Brien S, Giles F, Koller C, Keating M, Kantarjian H (2000) Cyclophosphamide, ara-C and topotecan (CAT) for patients with refractory or relapsed acute leukemia. Leuk Lymphoma 36:479-484 1:CAS:528:DC%2BD3MXovVKj
7. De la Rubia J, Regadera AA, Martin G, Cervera J, Sanz G, Martinez J, Jarque I, Garcia I, Andreu R, Moscardo F, Jimenez C, Molla S, Benlloch L, Sanz M (2002) FLAG-IDA regimen (fludarabine, cytarabine, idarubicin and G-CSF) in the treatment of patients with high-risk myeloid malignancies. Leuk Res 26:725-730 10.1016/S0145-2126(02)00003-6
8. Edenfield WJ, Gore SD (1999) Stage-specific application of allogeneic and autologous marrow transplantation in the management of acute myeloid leukemia. Semin Oncol 26:21-34 1:STN:280:DyaK1M7ntFGltQ%3D%3D
9. Estey E, Plunkett W, Gandhi V, Rios MB, Kantarjian H, Keating MJ (1993) Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia. Leuk Lymphoma 9:343-350 1:STN:280:ByyA2M%2FltlE%3D
10. Estey E, Thall P, Andreeff M (1994) Use of G-CSF before, during and after fludarabine plus Ara-C induction therapy of newly diagnosed AML or MDS: Comparison with fludarabine + Ara-C without G-CSF. J Clin Oncol 12:671-678 1:STN:280:ByuB3c7nvVQ%3D
11. Estey EH (2000) Treatment of relapsed and refractory acute myelogenous leukemia. Leukemia 14:476-479 10.1038/sj.leu.2401568
12. Ferra C, Berlanga J, Gallardo D, Ancin I, Marin D, Gonzalez JR, Peris J, Munoz J, Sarra J, Granena A (2000) Mitoxantrone, etoposide, carboplatinum and ara-C combination therapy (MECA) in refractory and relapsed acute leukemia. Leuk Lymphoma 39:583-590 1:CAS:528:DC%2BD3MXht1ynsbw%3D
13. Ferrara F, Melillo L, Montillo M, Leoni F, Pinto A, Mele G, Mirto S (1999) Fludarabine, cytarabine and G-CSF (FLAG) for the treatment of acute myeloid leukemia relapsing after autologous stem cell transplantation. Ann Hematol 78:380-384 10.1007/s002770050533
14. Gandhi V, Estey E, Keating MJ, Chucrallah A, Plunkett W (1996) Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: Pharmacokinetic, pharmacodynamic, and molecular interactions. Blood 87:256-264 1:CAS:528:DyaK28Xit1SitA%3D%3D
15. Gandhi V, Estey E, Keating MJ, Plunkett W (1993) Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clin Oncol 11:116-124 1:STN:280:ByyC3MrnsF0%3D
16. Hanel M, Friedrichsen K, Hanel A, Herbst R, Morgner A, Neser S, Nicklisch M, Teich M, Ehninger G, Fiedler F (2001) Mito-flag as salvage therapy for relapsed and refractory acute myeloid leukemia. Onkologie 24:356-360 10.1159/000055107
17. Hiddemann W, Martin WR, Sauerland CM, Heinecke A, Buchner T (1990) Definition of refractoriness against conventional chemotherapy in acute myeloid leukemia; a proposal based on the results of retreatment by thioguanine, cytosine arabinoside, and daunorubicin (TAD 9) in 150 patients with relapse after standardized first line therapy. Leukemia 4:184-188 1:STN:280:By%2BC1cbpsVI%3D
18. Hołowiecki J, Grosicki S, Robak T, Kyrcz-Krzemień S, Giebel S, Hellamnn A, Skotnicki A, Jȩdrzejczak WW, Konopka L, Kuliczkowski K, Zdziarska B, Dmoszyńska A, Mariańska B, Pluta A, Zawilska K, Komarnicki M, Kłoczko J, Sułek K, Haus O, Stella-Hołowiecka B, Baran W, Jakubas B, Paluszewska M, Wierzbowska A, Kiełbiñski M, Jagoda K, Polish Adult Leukemia Group (PALG) (2004) Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Mulitcenter, phase III study. Leukemia 18:989-997 10.1038/sj.leu.2403336
19. Huhmann IM, Watzke HH, Geissler K, Gisslinger H, Jager U, Knobl P, Pabinger I, Korninger L, Mannhalter C, Mitterbauer G, Schwarzinger I, Kahls P, Haas OA, Lechner K (1996) FLAG (fluadarabine, cytosine arabinoside, G-CSF) for refractory and relapsed acute myeloid leukemia. Ann Hematol 73:265-271 10.1007/s002770050239
20. Jackson G, Taylor P, Smith GM, Marcus R, Smith A, Chu P, Littlewood TJ, Duncombe A, Hutchinson M, Mehta AB, Johnson SA, Carey P, Mackie MJ, Ganly PS, Turner GE, Deane M, Schey S, Brookes J, Tollerfield SM, Wilson MP (2001) A multicentre, open, non-comparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukemia and de novo refractory anaemia with excess of blasts in transformation. Br J Haematol 112:127-137 10.1046/ j.1365-2141.2001.02551.x
21. Juliusson G, Hoglund M, Karlsson K, Lofgren C, Mollgard L, Paul C, Tidefelt U, Bjorkholm M, Leukemia Group of Middle Sweden (2003) Increased remissions from one course for intermediate-dose cytosine arabinoside and idarubicin in elderly acute myeloid leukaemia when combined with cladribine. A randomized population-based phase II study. Br J Haematol 123:810-818 10.1046/j.1365-2141.2003.04702.x
22. Kern W, Schleyer E, Braess J, Wittmer E, Ohnesorge J, Unterhalt M, Wormann B, Buchner T, Hiddemann W (2001) Efficacy of fludarabine, intermittent sequential high-dose cytosine arabinoside and mitoxantrone (FIS-HAM) salvage therapy in highly resistant acute leukemias. Ann Hematol 80:334-339 10.1007/s002770100293
23. Kern W, Schoch C, Haferlach T, Braess J, Unterhalt M, Wormann B, Buchner T, Hiddemann W, German AML Cooperative Group (2000) Multivariate analysis of prognostic factors in patients with refractory and relapsed acute myeloid leukemia undergoing sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy: Relevance of cytogenetic abnormalities. Leukemia 14:226-231 10.1038/sj.leu.2401668 AML
24. Kornblau SM, Gandhi V, Andreeff HM, Beran M, Kantarjian HM, Koller CA, O'Brien S, Plunkett W, Estey E (1996) Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults. Leukemia 10:1563-1569 1:STN:280:BymH3cvjs1Y%3D
25. Kristensen J, Nygren P, Liliemark J, Fridborg H, Killander A, Simonsson B, Oberg G, Larsson R (1994) Interactions between cladribine (2-chlorodeoxyadenosine) and standard anti-leukemic drugs in primary cultures of human tumour cells from patients with acute myelocytic leukemia. Leukemia 8:1712-1717 1:STN:280:ByqD3MbotFA%3D
26. Kufe D, Spriggs D, Egan EM, Munroe D (1984) Relationships among Ara-CTP pools, formation of (Ara-C) DNA and cytotoxicity of human leukemic cells. Blood 64:54-58 1:CAS:528:DyaL2cXltVeksrk%3D
27. Liu Yin JA, Wheatley K, Rees JK, Burnett AK, UK MRC Adult Leukemia Working Party (2001) Comparison of 'sequential' versus 'standard' chemotherapy as re-induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukemia (AML): Results of the UK medical research council AML-R trial. Br J Haematol 113:713-726 10.1046/ j.1365-2141.2001.02785.x
28. Montillo M, Mirto S, Petti MC, Latagliata R, Magrin S, Pinto A, Zagonel V, Mele G, Tedeschi A, Ferrara F (1998) Fludarabine, cytarabine and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia. Am J Hematol 58:105-109 10.1002/ (SICI)1096-8652(199806)58:2<105::AID-AJH3>3.0.CO;2-W
29. Nokes TJ, Johnson S, Harvey D, Goldstone AH (1997) FLAG is a useful regimen for poor prognosis adult myeloid leukemia and myelodysplastic syndromes. Leuk Lymphoma 27:93-101 1:CAS:528:DC%2BD3cXisFOhsr4%3D
30. Parker JE, Pagliuca A, Mijovic A, Cullis JO, Czepulkowski B, Rassam SM, Samaratunga IR, Grace R, Gover PA, Mufti GJ (1997) Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) in the treatment of poor risk myelodysplastic syndromes and acute myeloid leukaemia. Br J Haematol 99:939-944 10.1046/j.1365-2141.1997.4763281.x
31. Prebet T, Ducastelle S, Debotton S, Stamatoullas A, Deconinck E, Fruchart C, Gratecos N, Ifrah N, Dreyfus F, Fenaux P, Wattle E (2004) A phase II study of intensive chemotherapy with fludarabine, cytarabine, and mitoxantrone in P-glycoprotein-negative high-risk myelodysplastic syndromes. Hematol J 5:209-215 10.1038/sj.thj.6200363
32. Robak T, Wrzesień-Kuś A, Lech-Marańda E, Kowal M, Dmoszyńska A (2000) Combination regimen of cladribine (2-chlorodeoxyadenosine), cytarabine and G-CSF (CLAG) as induction therapy for patients with relapsed or refractory acute myeloid leukemia. Leuk Lymphoma 39:121-129 1:CAS:528:DC%2BD3MXht1ynsrk%3D
33. Robak T, Wrzesień-Kuś A (2002) The search for optimal treatment in relapsed and refractory acute myeloid leukemia. Leuk Lymphoma 43:281-291 10.1080/10428190290006053
34. Robak T (2003) Purine nucleoside analogues in the treatment of myeloid leukemia. Leuk Lymphoma 44:391-409 10.1080/1042819021000035608
35. Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A, Paietta E, Willman CL, Head DR, Rowe JM, Forman SJ, Appelbaum FR (2000) Karyotypic analysis predicts outcome of pre-remission and postremission therapy in adult acute myeloid leukemia: A Southwest Oncology Group/ Eastern Cooperative Oncology Group study. Blood 96:4075-4083 1:CAS:528:DC%2BD3cXosl2hsbo%3D
36. Steinmetz HT, Schulz A, Staib P, Scheid C, Glasmacher A, Neufang A, Franklin J, Tesch H, Diehl V, Dias Wickramanayake P (1999) Phase-II trial of idarubicin, fludarabine, cytosine arabinoside, and filgrastim (Ida-FLAG) for treatment of refractory, relapsed, and secondary AML. Ann Hematol 78:418-425 10.1007/s002770050541
37. Tallman MS, Lee S, Sikic BI, Paietta E, Wiernik PH, Bennett JM, Rowe JM (1999) Mitoxantrone, etoposide and cytarabine plus cyclosporine for patients with relapsed or refractory acute myeloid leukemia. Cancer 85:358-367 10.1002/ (SICI)1097-0142(19990115)85:2<358::AID-CNCR13>3.0.CO;2-0
38. Visani G, Tosi P, Zinzani PL, Manfroi S, Ottaviani E, Testoni N, Clavio M, Cenacchi A, Gamberi B, Carrara P, Gobbi M, Tura S (1994) FLAG (fludarabine+high dose cytarabine+G-CSF): An effective and tolerable protocol for the treatment of "poor risk" acute myeloid leukemia. Leukemia 8:1842-1846 1:STN:280:ByqD2MjivFY%3D
39. Wrzesień-Kuś A, Robak T, Lech-Marańda E, Wierzbowska A, Dmoszyńska A, Kowal M, Holowiecki J, Kyrcz-Krzemien S, Grosicki S, Maj S, Hellmann A, Skotnicki A, Jedrzejczak W, Kuliczkowski K (2003) A multicenter, open, non-comparative phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, and G-CSF as induction therapy in refractory acute myeloid leukemia - a report of the Polish Adult Leukemia Group (PALG). Eur J Haematol 71:155-162 10.1034/j.1600-0609.2003.00122.x